


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents,  
Washington, D.C. 20231.

#20  
GRB

PATENT

Attorney Docket No. 15270-001420



TOWNSEND and TOWNSEND and CREW LLP

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re application of:

M. Bendig et al.

Application No.: 08/561,521

Filed: November 21, 1995

For: HUMANIZED ANTIBODIES  
AGAINST LEUKOCYTE ADHESION  
MOLECULE VLA-4

Examiner: P. Gambel

OCT 28 2002

Art Unit: 1806

TECH CENTER 1600/2900

DECLARATION OF  
TED YEDNOCK

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

I, Ted Yednock, state as follows:

1. I am a co-inventor of the above-captioned application, and an employee of Athena Neurosciences, the assignee of the above-captioned invention.
2. I understand the Examiner has cited Monshizadegan et al., Agents Actions 39, C177-C179 (1993) as disclosing the mouse 21.6 antibody. I am a co-author of the cited paper. All of my co-authors are or were employees of Athena Neurosciences or Wyeth-Ayerst Research.
3. The mouse 21.6 antibody has not been made available to the public before the filing date of the present application (November 21, 1995) notwithstanding that the antibody has been discussed in the above Monshizadegan et al. reference. At the filing date of


PATENT

M. Bendig et al.  
Application No.: 08/561,521  
Page 2

the application, custody of the antibody has been confined to Athena Neurosciences, Wyeth-Ayerst Research, and their employees.

4. I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issues thereon.

Date: 8/4/97



Dr. Ted Yednock

H:\HOME\VOL\WORK\15270\14-2\YEDNOCK.DEC

TOTAL P.03